MedTech Europe's Brexit Challenge: Don't Forget The Kid In The EU Divorce
The UK continues to press for favorable trading and regulatory conditions with the EU in its Brexit planning. But EU negotiators seem likely to play it by the book, with no favors shown. The medtech industry watched as the EU withdrawal agreement was approved by the EU27 at the March 2018 Euro Summit. Some weeks prior to that, MedTech Europe chief executive Serge Bernasconi told In Vivo of his fears for EU medtech if the industry was too slow in preparing for UK withdrawal.
You may also be interested in...
With the UK scheduled to leave the EU one year, the UK medtech and lifesciences industries were becoming increasingly concerned about the government's lack ofplanning and the risk of being left high and dry in the post-Brexit environment. But the UK has bought more time now that the EU agreed to a withdrawal transition phase until the end of 2020. There are potentially meaningful positives in the agreement for medtechs on either side of the English Channel.
Norway’s Pre Diagnostics uses the intracellular approach to neurodegenerative disease diagnosis. It believes its technology will open up a world of precision medicine for Alzheimer’s disease patients.
Device sales centers are being required to update the government’s product tracking system with sales data under a series of recent changes spurred partly by COVID-19.